OPKO Health Inc
OPK1.380USD
-0.020-1.43%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.06BValor de mercado
PerdaP/L TTM
Mais detalhes de OPKO Health Inc Empresa
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Informações de OPKO Health Inc
Código da empresaOPK
Nome da EmpresaOPKO Health Inc
Data de listagemNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Número de funcionários2997
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ Global Select Consolidated
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaOPK
Data de listagemNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Executivos da empresa OPKO Health Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Por RegiãoUSD
Nome
Receita
Proporção
United States
114.88M
73.26%
Chile
16.00M
15.83%
Ireland
11.74M
11.61%
Spain
6.72M
6.65%
Mexico
6.30M
6.23%
Outro
-54.55M
-13.59%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Outro
50.53%
Investidores
Investidores
Proporção
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Outro
50.53%
Tipos de investidores
Investidores
Proporção
Corporation
37.85%
Investment Advisor
12.39%
Individual Investor
10.57%
Hedge Fund
7.62%
Investment Advisor/Hedge Fund
5.83%
Research Firm
1.05%
Bank and Trust
0.16%
Pension Fund
0.12%
Family Office
0.02%
Outro
24.39%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
455
208.86M
27.21%
-55.45M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Frost Gamma Investments Trust
220.16M
27.74%
+360.00K
+0.16%
Sep 30, 2025
Rubric Capital Management LP
47.79M
6.02%
-915.40K
-1.88%
Jun 30, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
The Vanguard Group, Inc.
38.16M
4.81%
+8.74M
+29.70%
Jun 30, 2025
Hsiao (Jane H)
33.13M
4.17%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.22M
3.55%
+3.45M
+13.93%
Jun 30, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.42M
1.31%
+2.00M
+23.68%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.55%
SPDR S&P Health Care Services ETF
0.49%
VanEck Israel ETF
0.15%
Humankind US Stock ETF
0.11%
iShares U.S. Healthcare Providers ETF
0.11%
Goldman Sachs Innovate Equity ETF
0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.55%
SPDR S&P Health Care Services ETF
Proporção0.49%
VanEck Israel ETF
Proporção0.15%
Humankind US Stock ETF
Proporção0.11%
iShares U.S. Healthcare Providers ETF
Proporção0.11%
Goldman Sachs Innovate Equity ETF
Proporção0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.06%
iShares Biotechnology ETF
Proporção0.05%
iShares Russell 2000 Value ETF
Proporção0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.04%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
